Beyond standard adjuvant therapy for colon cancer: Role of nonstandard interventions

Seminars in Oncology

Volumn 38, Issue 4, 2011, Pages 533-541

  Meyerhardt, Jeffrey A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C PEPTIDE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ESTROGEN; FLUOROURACIL; FOLINIC ACID; INSULIN; IRINOTECAN; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; ROFECOXIB; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; VITAMIN D;

ADJUVANT THERAPY; ALCOHOL CONSUMPTION; BODY WEIGHT; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CIGARETTE SMOKING; CLINICAL TRIAL (TOPIC); COLON CANCER; COLON RESECTION; COLORECTAL CANCER; DIET; DISEASE FREE SURVIVAL; EXERCISE; FOOD INTAKE; HUMAN; LIFESTYLE MODIFICATION; MULTIPLE CYCLE TREATMENT; OBESITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RED MEAT; REVIEW; RISK REDUCTION;

EID: 79960992876     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.05.007     Document Type: Article

References (78)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin.
2. Wei EK, Giovannucci E, Wu K, et al. Comparison of risk factors for colon and rectal cancer. Int J Cancer. 2004; 108:433-42. (Pubitemid 37549610)
3. Samad AK, Taylor RS, Marshall T, Chapman MA. A metaanalysis of the association of physical activity with reduced risk of colorectal cancer. Colorectal Dis. 2005;7: 204-13. (Pubitemid 40637417)
4. Vainio H, Kaaks R, Bianchini F. Weight control and physical activity in cancer prevention: international evaluation of the evidence. Eur J Cancer Prev. 2002;11 Suppl 2:S94 -100.
5. Wolin KY, Yan Y, Colditz GA, Lee IM. Physical activity and colon cancer prevention: a meta-analysis. Br J Cancer. 2009;100:611-6.
6. Haydon AM, Macinnis RJ, English DR, Giles GG. Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut. 2006;55:62-7. (Pubitemid 41820637)
7. Haydon AM, Macinnis RJ, English DR, Morris H, Giles GG. Physical activity, insulin-like growth factor 1, insulin- like growth factor binding protein 3, and survival from colorectal cancer. Gut. 2006;55:689-94.
8. Meyerhardt JA, Giovannucci EL, Holmes MD, et al. Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol. 2006;24:3527-34. (Pubitemid 46630522)
9. Meyerhardt JA, Giovannucci EL, Ogino S, et al. Physical activity and male colorectal cancer survival. Arch Intern Med. 2009;169:2102-8.
10. Meyerhardt JA, Heseltine D, Niedzwiecki D, et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2006;24:3535-41. (Pubitemid 46630523)
11. Courneya KS, Booth CM, Gill S, et al. The Colon Health and Life-Long Exercise Change trial: a randomized trial of the National Cancer Institute of Canada Clinical Trials Group. Curr Oncol. 2008;15:271-8.
12. Blanchard CM, Courneya KS, Stein K. Cancer survivors' adherence to lifestyle behavior recommendations and associations with health-related quality of life: results from the American Cancer Society's SCS-II. J Clin Oncol. 2008;26:2198-204.
13. Courneya KS, Friedenreich CM. Relationship between exercise pattern across the cancer experience and current quality of life in colorectal cancer survivors. J Altern Complement Med. 1997;3:215-26. (Pubitemid 127531542)
14. Courneya KS, Friedenreich CM. Physical exercise and quality of life following cancer diagnosis: a literature review. Ann Behav Med. 1999;21:171-9. (Pubitemid 29445396)
15. Johnson BL, Trentham-Dietz A, Koltyn KF, Colbert LH. Physical activity and function in older, long-term colorectal cancer survivors. Cancer Causes Control. 2009; 20:775-84.
16. Lynch BM, Cerin E, Owen N, Aitken JF. Associations of leisure-time physical activity with quality of life in a large, population-based sample of colorectal cancer survivors. Cancer Causes Control. 2007;18:735-42. (Pubitemid 46988241)
17. Peddle CJ, Au HJ, Courneya KS. Associations between exercise, quality of life, and fatigue in colorectal cancer survivors. Dis Colon Rectum. 2008;51:1242-8.
18. Courneya KS, Friedenreich CM, Quinney HA, Fields AL, Jones LW, Fairey AS. A randomized trial of exercise and quality of life in colorectal cancer survivors. Eur J Cancer Care (Engl). 2003;12:347-57. (Pubitemid 37550287)
19. Meyerhardt JA, Catalano PJ, Haller DG, et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer. 2003; 98:484-95. (Pubitemid 36885987)
20. Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol. 2008;26:4109-15.
21. Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol. 2004; 22:648-57. (Pubitemid 41095068)
22. Dignam JJ, Polite BN, Yothers G, et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst. 2006;98: 1647-54. (Pubitemid 44811647)
23. Shibakita M, Yoshimura H, Tachibana M, Ueda S, Nagasue N. Body mass index influences long-term outcome in patients with colorectal cancer. Hepatogastroenterology. 2010;57:62-9.
24. Hines R, Shanmugam C, Waterbor J, et al. Effect of comorbidity and body mass index on the survival of African-American and caucasian patients with colon cancer. Cancer. 2009;115:5798-806.
25. Giovannucci E. Diet, body weight, and colorectal cancer: a summary of the epidemiologic evidence. J Womens Health (Larchmt). 2003;12:173-82. (Pubitemid 36546762)
26. Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol. 2005;23:1370-8.
27. Camoriano JK, Loprinzi CL, Ingle JN, Therneau TM, Krook JE, Veeder MH. Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol. 1990; 8:1327-34. (Pubitemid 20252304)
28. Caan BJ, Emond JA, Natarajan L, et al. Post-diagnosis weight gain and breast cancer recurrence in women with early stage breast cancer. Breast Cancer Res Treat. 2006;99:47-57. (Pubitemid 44168602)
29. Caan BJ, Kwan ML, Hartzell G, et al. Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer. Cancer Causes Control. 2008;19:1319-28.
30. Giovannucci E. Modifiable risk factors for colon cancer. Gastroenterol Clin North Am. 2002;31:925-43. (Pubitemid 35403506)
31. Thun MJ, Calle EE, Namboodiri MM, et al. Risk factors for fatal colon cancer in a large prospective study. J Natl Cancer Inst. 1992;84:1491-500.
32. Martinez ME. Primary prevention of colorectal cancer: lifestyle, nutrition, exercise. Recent Results Cancer Res. 2005;166:177-211.
33. Bostick RM, Potter JD, Kushi LH, et al. Sugar, meat, and fat intake, and non-dietary risk factors for colon cancer incidence in Iowa women (United States). Cancer Causes Control. 1994;5:38-52. (Pubitemid 24066592)
34. Slattery ML, French TK, Egger MJ, Lyon JL. Diet and survival of patients with colon cancer in Utah: is there an association? Int J Epidemiol. 1989;18:792-7. (Pubitemid 20030191)
35. Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA. 2007; 298:754-64. (Pubitemid 47263158)
36. Dray X, Boutron-Ruault MC, Bertrais S, Sapinho D, Benhamiche- Bouvier AM, Faivre J. Influence of dietary factors on colorectal cancer survival. Gut. 2003;52:868-73. (Pubitemid 36613495)
37. Meyerhardt JA, Fuchs C. Cancer recurrence and survival associated with dietary patterns in stage III colon cancerreply. JAMA. 2007;298:2263. (Pubitemid 350146230)
38. Giovannucci E. Insulin and colon cancer. Cancer Causes Control. 1995;6:164-79.
39. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr. 2001;131 suppl:3109S-20S.
40. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc. 2001;60:91-106. (Pubitemid 32183103)
41. Schoen RE, Tangen CM, Kuller LH, et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst. 1999;91:1147-54. (Pubitemid 29330553)
42. Kaaks R, Toniolo P, Akhmedkhanov A, et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst. 2000;92:1592-600.
43. Palmqvist R, Stattin P, Rinaldi S, et al. Plasma insulin, IGF-binding proteins-1 and -2 and risk of colorectal cancer: a prospective study in northern Sweden. Int J Cancer. 2003;107:89-93. (Pubitemid 37100090)
44. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein- 3. J Natl Cancer Inst. 1999;91:620-5. (Pubitemid 29194048)
45. Manousos O, Souglakos J, Bosetti C, et al. IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer. 1999;83: 15-7. (Pubitemid 29409470)
46. Renehan AG, Painter JE, Atkin WS, Potten CS, Shalet SM, O'Dwyer ST. High-risk colorectal adenomas and serum insulin-like growth factors. Br J Surg. 2001;88:107-13. (Pubitemid 32066068)
47. Palmqvist R, Hallmans G, Rinaldi S, et al. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut. 2002;50:642-6. (Pubitemid 34407490)
48. Probst-Hensch NM, Yuan JM, Stanczyk FZ, Gao YT, Ross RK, Yu MC. IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai. Br J Cancer. 2001;85:1695-9. (Pubitemid 34081515)
49. Pollak MN, Perdue JF, Margolese RG, Baer K, Richard M. Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Lett. 1987;38: 223-30. (Pubitemid 18005853)
50. Guo YS, Narayan S, Yallampalli C, Singh P. Characterization of insulinlike growth factor I receptors in human colon cancer. Gastroenterology. 1992;102:1101-8.
51. Watkins L, Lewis L, Levine A. Characterization of the synergistic effect of insulin and transferrin and the regulation of their receptors on a human colon carcinoma cell line. Int J Cancer. 1990;45:372-375. (Pubitemid 20061396)
52. Koenuma M, Yamori T, Tsuruo T. Insulin and insulin-like growth factor 1 stimulate proliferation of metastatic variants of colon carcinoma 26. Jpn J Cancer Res. 1989;80: 51-8. (Pubitemid 20027198)
53. Bjork J, Nilsson J, Hultcrantz R, Johansson C. Growth-regulatory effects of sensory neuropeptides, epidermal growth factor, insulin, and somatostatin on the nontransformed intestinal epithelial cell line IEC-6 and the colon cancer cell line HT 29. Scand J Gastroenterol. 1993;28:879-84. (Pubitemid 23294761)
54. Ma J, Giovannucci E, Pollak M, Leavitt A, Tao Y, Gaziano JM, Stampfer MJ. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst. 2004;96:546-53. (Pubitemid 38559579)
55. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891-9. (Pubitemid 36297997)
56. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873-84. (Pubitemid 44315980)
57. Cross JT, Poole EM, Ulrich CM. A review of gene-drug interactions for nonsteroidal anti-inflammatory drug use in preventing colorectal neoplasia. Pharmacogenomics J. 2008;8:237-47. (Pubitemid 352042411)
58. Chan AT. Aspirin, non-steroidal anti-inflammatory drugs and colorectal neoplasia: future challenges in chemoprevention. Cancer Causes Control. 2003;14:413-8. (Pubitemid 36999975)
59. Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology. 2006;131:1674-82. (Pubitemid 44958508)
60. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005;294:914-23. (Pubitemid 41215460)
61. Ji H, Ramsey MR, Hayes DN, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature. 2007;448: 807-10. (Pubitemid 47266337)
62. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883-90. (Pubitemid 36297996)
63. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302: 649-59.
64. Fuchs C, Meyerhardt JA, Heseltine DL, et al. Influence of regular aspirin use on survival for patients with stage III colon cancer: findings from Intergroup trial CALGB 89803 [abstract 3530]. J Clin Oncol. 2005;23:16S.
65. Kerr DJ, Dunn JA, Langman MJ, et al. VICTOR: a phase III placebo-controlled trial of rofecoxib in colorectal cancer patients following surgical resection [abstract 4038]. J Clin Oncol. 2008;26 suppl.
66. Giovannucci E. Epidemiological evidence for vitamin D and colorectal cancer. J Bone Miner Res. 2007;22 suppl 2:V81-5.
67. Gorham ED, Garland CF, Garland FC, et al. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am J Prev Med. 2007;32: 210-6. (Pubitemid 46223622)
68. Newmark HL, Wargovich MJ, Bruce WR. Colon cancer and dietary fat, phosphate, and calcium: a hypothesis. J Natl Cancer Inst. 1984;72:1323-5. (Pubitemid 14124258)
69. Walters MR. Newly identified actions of the vitamin D endocrine system. Endocr Rev. 1992;13:719-64. (Pubitemid 23037213)
70. Shabahang M, Buras RR, Davoodi F, Schumaker LM, Nauta RJ, Evans SR. 1,25-Dihydroxyvitamin D3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res. 1993;53: 3712-8.
71. Evans SR, Schwartz AM, Shchepotin EI, Uskokovic M, Shchepotin IB. Growth inhibitory effects of 1,25-dihydroxyvitamin D3 and its synthetic analogue, 1alpha,25- dihydroxy-16-ene-23yne-26,27-hexafluoro-19-nor-cholecalcifero l (Ro 25-6760), on a human colon cancer xenograft. Clin Cancer Res. 1998;4:2869-76. (Pubitemid 28523517)
72. Goodwin PJ. Vitamin D in cancer patients: above all, do no harm. J Clin Oncol. 2009;27:2117-9.
73. Ng K, Meyerhardt JA, Wu K, et al. Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. J Clin Oncol. 2008;26:2984-91.
74. Ng K, Wolpin BM, Meyerhardt JA, et al. Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer. Br J Cancer. 2009;101: 916-23.
75. Giovannucci E, Martinez ME. Tobacco, colorectal cancer, and adenomas: a review of the evidence. J Natl Cancer Inst. 1996;88:1717-30. (Pubitemid 26405009)
76. Heineman EF, Zahm SH, McLaughlin JK, Vaught JB. Increased risk of colorectal cancer among smokers: results of a 26-year follow-up of US veterans and a review. Int J Cancer. 1994;59:728-38.
77. Rocha RL, Hilsenbeck SG, Jackson JG, et al. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res. 1997;3:103-9. (Pubitemid 27079451)
78. Tartter PI, Slater G, Papatestas AE, Aufses AH Jr. Cholesterol, weight, height, Quetelet's index, and colon cancer recurrence. J Surg Oncol. 1984;27:232-5. (Pubitemid 15179689)